title: Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study.
abstract: BACKGROUND
  Indacaterol is a novel once-daily ultra long-acting β2-agonist for the treatment of chronic obstructive pulmonary disease. It is known that β2-agonists, like other adrenergic compounds, can prolong the QT-interval. This thorough QT/QTc study (as per ICH E14 guideline) evaluated the effect of indacaterol on the QT interval in healthy subjects.
  
  
  METHODS
  In this randomized, double-blind, parallel-group, placebo- and positive-controlled (open-label moxifloxacin) study, non-smoking healthy subjects (18-55 years, body mass index: 18.5-32.0 kg/m2) were randomized (4:4:2:4:1) to 14-day treatment with once-daily indacaterol (150 μg, 300 μg, or 600 μg), placebo, or placebo/moxifloxacin (double-blind 14-day treatment with placebo and a single open-label dose of 400 mg moxifloxacin on Day 14). The primary endpoint was the change from baseline on Day 14 in QTcF (QT interval corrected for heart rate using Fridericia's formula).
  
  
  RESULTS
  In total, 404 subjects were randomized to receive indacaterol (150 [n = 108], 300 [n = 108], 600 μg [n = 54]), placebo (n = 107), or placebo/moxifloxacin (n = 27); 388 subjects completed the study. Maximal time-matched mean (90% confidence intervals) treatment differences from placebo in QTcF change from baseline on Day 14 were 2.66 (0.55, 4.77), 2.98 (1.02, 4.93) and 3.34 (0.86, 5.82) ms for indacaterol 150 μg, 300 μg and 600 μg, respectively. Study sensitivity was confirmed with moxifloxacin demonstrating a significant maximal time-matched QTcF prolongation of 13.90 (10.58, 17.22) ms compared to placebo. All indacaterol doses were well tolerated.
  
  
  CONCLUSIONS
  Indacaterol, at doses up to 600 μg once daily (2-4 times the therapeutic dose) does not have any clinically relevant effect on the QT interval.
authors: Novartis Horsham Research Centre, Horsham, West Sussex RH12 5AB, UK. sanjeev.khindri@novartis.com
authors: Sanjeev
authors: S
authors: Khindri
authors: Ronald
authors: R
authors: Sabo
authors: Stuart
authors: S
authors: Harris
authors: Ralph
authors: R
authors: Woessner
authors: Simon
authors: S
authors: Jennings
authors: Anton F
authors: AF
authors: Drollmann
references: Thorax. 2010 Jun;65(6):473-9
references: 20522841
references: Open Respir Med J. 2009 Mar 12;3:27-30
references: 19452036
references: Respir Med. 2011 Apr;105(4):571-9
references: 21227674
references: Expert Opin Investig Drugs. 2005 Jul;14(7):775-83
references: 16022567
references: J Pharmacol Exp Ther. 2006 May;317(2):762-70
references: 16434564
references: Eur Respir J. 2007 Mar;29(3):575-81
references: 17135231
references: Fed Regist. 2005 Oct 20;70(202):61134-5
references: 16237860
references: Pulm Pharmacol Ther. 2007;20(6):740-9
references: 17088091
references: Am J Respir Crit Care Med. 2010 Jul 15;182(2):155-62
references: 20463178
references: Clin Ther. 2006 Apr;28(4):582-90
references: 16750469
references: Clin Pharmacol Ther. 2007 Jan;81(1):108-13
references: 17186008
references: Pulm Pharmacol Ther. 2010 Jun;23(3):165-71
references: 20080201
references: Clin Pharmacol Ther. 2000 Dec;68(6):658-66
references: 11180026
references: Chest. 2004 Jun;125(6):2309-21
references: 15189956
references: Curr Med Res Opin. 2009 Feb;25(2):463-70
references: 19192991
references: Respir Med. 2008 Jul;102(7):1033-44
references: 18479895
references: Int J Clin Pharmacol Ther. 2011 Feb;49(2):153-61
references: 21255532